TNFRSF9 and neoplasm: Its lead trispecific molecule, NM21-1480 (PD-L1/4-1BB/albumin), allows conditional 4-1BB co-stimulation, eliminates hepatotoxicity seen with prior agents, and induces tumor regression in xenografts (249).